Antitumor immunity and cancer stem cells

Annals of the New York Academy of Sciences

Volumn 1176, Issue , 2009, Pages 154-169

  Schatton, Tobias ^a   Frank, Markus H ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

ABCB5; Anergy; Cancer stem cell; Immunity; Immunotherapy; MART 1; Melanoma; Regulatory T cells; T cell activation; Tolerance

Indexed keywords

MELAN A; MULTIDRUG RESISTANCE PROTEIN;

CANCER RESISTANCE; CANCER STEM CELL; CELL ACTIVATION; CELL RENEWAL; CLONAL ANERGY; CONFERENCE PAPER; CORRELATION ANALYSIS; HOST RESISTANCE; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; MELANOMA; NONHUMAN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SKIN CARCINOGENESIS; TUMOR IMMUNITY;

EID: 70349552398     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04568.x     Document Type: Conference Paper

References (139)

1. Al-Hajj, M. et al. 2003. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 100: 3983-3988 (Pubitemid 36418143)
2. Bonnet, D. & J.E. Dick. 1997. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3: 730-737
3. Dalerba, P. et al. 2007. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. USA 104: 10158-10163
4. Hermann, P.C. et al. 2007. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1: 313-323
5. Lapidot, T. et al. 1994. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367: 645-648
6. Li, C. et al. 2007. Identification of pancreatic cancer stem cells. Cancer Res. 67: 1030-1037
7. O'Brien, C.A. et al. 2007. A human colon cancer cell capable of initiating tumour growth in immun-odeficient mice. Nature 445: 106-110
8. Prince, M.E. et al. 2007. Identification of a subpop-ulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc. Natl. Acad. Sci. USA 104: 973-978
9. Ricci-Vitiani, L. et al. 2007. Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115
10. Schatton, T. et al. 2008. Identification of cells initiating human melanomas. Nature 451: 345-349
11. Singh, S.K. et al. 2003. Identification of a cancer stem cell in human brain tumors. Cancer Res. 63: 5821-5828
12. Yang, Z.F. et al. 2008. Significance of CD90(+) cancer stem cells in human liver cancer. Cancer Cell. 13: 153-166
13. Zhang, S. et al. 2008. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 68: 4311-4320
14. Reya, T. et al. 2001. Stem cells, cancer, and cancer stem cells. Nature 414: 105-111
15. Bao, S. et al. 2006. Glioma stem cells promote ra-dioresistance by preferential activation of the DNA damage response. Nature 444: 756-760
16. Bao, S. et al. 2006. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothe-lial growth factor. Cancer Res. 66: 7843-7848
17. Li, X. et al. 2008. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl. Cancer Inst. 100: 672-679
18. Piccirillo, S.G. et al. 2006. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 444: 761-765
19. Bao, S. et al. 2008. Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res. 68: 6043-6048
20. Schatton, T. & M.H. Frank. 2008. Cancer stem cells and human malignant melanoma. Pigment Cell Melanoma Res. 21: 39-55
21. Frank, N.Y. et al. 2005. ABCB5-mediated doxoru-bicin transport and chemoresistance in human malignant melanoma. Cancer Res. 65: 4320-4333
22. Huang, Y. et al. 2004. Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res. 64: 4294-4301
23. Keshet, G.I. et al. 2008. MDR1 expression identifies human melanoma stem cells. Biochem. Biophys. Res. Commun. 368: 930-936
24. Sousa, J.F. & E.M. Espreafico. 2008. Suppression subtractive hybridization profiles of radial growth phase and metastatic melanoma cell lines reveal novel potential targets. BMC Cancer 8: 19
25. Hoek, K.S. et al. 2008. In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res. 68: 650-656
26. Hoek, K.S. et al. 2009. Stemming the flood. Pigment Cell Melanoma Res. 22: 6-7
27. Suryo Rahmanto, Y., L.L. Dunn & D.R. Richardson. 2007. Identification of distinct changes in gene expression after modulation of melanoma tumor antigen p97 (melanotransferrin) in multiple models in vitro and in vivo. Carcinogenesis 28: 2172-2183
28. Frank, M.H. & M.H. Sayegh. 2004. Immunomod-ulatory functions of mesenchymal stem cells. Lancet 363: 1411-1412
29. Le Blanc, K. et al. 2004. Treatment of severe acute graft-versus-host disease with third party haploiden-tical mesenchymal stem cells. Lancet 363: 1439-1441
30. Le Blanc, K. & O. Ringden. 2007. Immunomodu-lation by mesenchymal stem cells and clinical experience. J. Intern. Med. 262: 509-525 (Pubitemid 47620502)
31. Grulich, A.E. et al. 2007. Incidence of cancers in people with HIV/AIDS compared with immuno-suppressed transplant recipients: a meta-analysis. Lancet 370: 59-67
32. Shankaran, V. et al. 2001. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107-1111
33. Haanen, J.B. et al. 2006. Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunol. Immunother. 55: 451-458
34. Quintana, E. et al. 2008. Efficient tumour formation by single human melanoma cells. Nature 456: 593-598
35. Mapara, M.Y. & M. Sykes. 2004. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J. Clin. Oncol. 22: 1136-1151
36. Rosenberg, S.A. et al. 2008. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 8: 299-308
37. Ramsdell, F. & B.J. Fowlkes. 1990. Clonal deletion versus clonal anergy: the role of the thymus in inducing self tolerance. Science 248: 1342-1348
38. Kappler, J.W., N. Roehm & P. Marrack. 1987. T cell tolerance by clonal elimination in the thymus. Cell 49: 273-280
39. Ramsdell, F., T. Lantz & B.J. Fowlkes. 1989. A non-deletional mechanism of thymic self tolerance. Science 246: 1038-1041
40. Ramsdell, F. & B.J. Fowlkes. 1992. Maintenance of in vivo tolerance by persistence of antigen. Science 257: 1130-1134
41. Surh, C.D. & J. Sprent. 1994. T-cell apoptosis detected in situ during positive and negative selection in the thymus. Nature 372: 100-103
42. Theobald, M. et al. 1997. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J. Exp. Med. 185: 833-841
43. Rosenberg, S.A. 1999. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10: 281-287
44. Houghton, A.N., J.S. Gold & N.E. Blachere. 2001. Immunity against cancer: lessons learned from melanoma. Curr. Opin. Immunol. 13: 134-140
45. Jager, E. et al. 2000. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc. Natl. Acad. Sci. USA 97: 12198-12203
46. Lee, P.P. et al. 1999. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5: 677-685
47. Stockert, E. et al. 1998. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J. Exp. Med. 187: 1349-1354
48. Khong, H.T., Q.J. Wang & S.A. Rosenberg. 2004. Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression. J. Immunother. 27: 184-190
49. Davidson, R.L. 1972. Regulation of malanin synthesis in mammalian cells: effect of gene dosage on the expression of differentiation. Proc. Natl. Acad. Sci. USA 69: 951-955
50. Guerry, D.T. et al. 1984. HLA-DR histocompat-ibility leukocyte antigens permit cultured human melanoma cells from early but not advanced disease to stimulate autologous lymphocytes. J. Clin. Invest. 73: 267-271
51. Aptsiauri, N. et al. 2007. Role of altered expression of HLA class I molecules in cancer progression. Adv. Exp. Med. Biol. 601: 123-131
52. Le Blanc, K. et al. 2003. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp. Hematol. 31: 890-896
53. Cabrera, T. et al. 2007. HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination. Cancer Im-munol. Immunother. 56: 709-717
54. Carretero, R. et al. 2008. Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy. Immunogenetics 60: 439-447
55. van Houdt, I.S. et al. 2008. Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression. Int. J. Cancer 123: 609-615
56. Kawakami, Y. et al. 2000. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. J. Immunother. 23: 17-27
57. Staveley-O'Carroll, K. et al. 1998. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA 95: 1178-1183
58. Strand, S. et al. 1996. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells-a mechanism of immune evasion? Nat. Med. 2: 1361-1366
59. Andreola, G. et al. 2002. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J. Exp. Med. 195: 1303-1316
60. Gastman, B.R. et al. 1999. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res. 59: 5356-5364
61. Hahne, M. et al. 1996. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274: 1363-1366
62. Hallermalm, K. et al. 2004. Autocrine secretion of Fas ligand shields tumor cells from Fas-mediated killing by cytotoxic lymphocytes. Cancer Res. 64: 6775-6782
63. Neuber, K. & B. Eidam. 2006. Expression of Fas ligand (CD95L) in primary malignant melanoma and melanoma metastases is associated with overall survival. Onkologie 29: 361-365
64. Nakashima, M., K. Sonoda & T. Watanabe. 1999. Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1. Nat. Med. 5: 938-942
65. Benvenuto, F. et al. 2007. Human mesenchymal stem cells promote survival of T cells in a quiescent state. Stem Cells 25: 1753-1760
66. Liu, J. et al. 2004. Suppression of human peripheral blood lymphocyte proliferation by immortalized mesenchymal stem cells derived from bone marrow of Banna Minipig inbred-line. Transplant Proc. 36: 3272-3275
67. Matsushima, T. et al. 2001. Receptor binding cancer antigen expressed on SiSo cells, a novel regulator of apoptosis of erythroid progenitor cells. Blood 98: 313-321
68. Taylor, A. et al. 2006. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells. Immunology 117: 433-442
69. Di Nicola, M. et al. 2002. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99: 3838-3843
70. Chen, Q. et al. 1994. Production of IL-10 by melanoma cells: examination of its role in immuno-suppression mediated by melanoma. Int. J. Cancer 56: 755-760
71. Gorelik, L. & R.A. Flavell. 2001. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat. Med. 7: 1118-1122
72. Inge, T.H. et al. 1992. Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1. Cancer Res. 52: 1386-1392
73. Shipitsin, M. et al. 2007. Molecular definition of breast tumor heterogeneity. Cancer Cell. 11: 259-273
74. Rothstein, D.M. & M.H. Sayegh. 2003. T-cell cos- timulatory pathways in allograft rejection and tolerance. Immunol. Rev. 196: 85-108
75. Frank, M.H. et al. 2001. Specific MDR1 P-glycoprotein blockade inhibits human alloimmune T cell activation in vitro. J. Immunol. 166: 2451-2459
76. Pendse, S.S. et al. 2006. P-glycoprotein functions as a differentiation switch in antigen presenting cell maturation. Am. J. Transplant. 6: 2884-2893
77. Jenkins, M.K. et al. 1991. CD28 delivers a costim-ulatory signal involved in antigen-specific IL-2 production by human T cells. J. Immunol. 147: 2461-2466
78. Kroczek, R.A., H.W. Mages & A. Hutloff. 2004. Emerging paradigms of T-cell co-stimulation. Curr. Opin. Immunol. 16: 321-327
79. Schwartz, R.H. 1990. A cell culture model for T lymphocyte clonal anergy. Science 248: 1349-1356
80. Beyth, S. et al. 2005. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 105: 2214-2219
81. Jiang, X.X. et al. 2005. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 105: 4120-4126
82. Sotomayor, E.M. et al. 2001. Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lym-phoma progression. Blood 98: 1070-1077
83. Sotomayor, E.M. et al. 1999. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat. Med. 5: 780-787
84. Dunn, G.P. et al. 2002. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3: 991-998
85. Brocker, E.B., L. Suter & C. Sorg. 1984. HLA-DR antigen expression in primary melanomas of the skin. J. Invest. Dermatol. 82: 244-247
86. Becker, J.C. et al. 1993. Tumor escape mechanisms from immunosurveillance: induction of unresponsiveness in a specific MHC-restricted CD4+ human T cell clone by the autologous MHC class II +melanoma. Int. Immunol. 5: 1501-1508
87. Bai, Y. et al. 2002. L-selectin-dependent lymphoid occupancy is required to induce alloantigen-specific tolerance. J. Immunol. 168: 1579-1589
88. Ruiter, D.J. et al. 1991. MHC antigens in human melanomas. Semin. Cancer Biol. 2: 35-45
89. Romieu-Mourez, R. et al. 2007. Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFN-gamma, TGF-beta, and cell density. J. Immunol. 179: 1549-1558
90. Augello, A. et al. 2005. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur. J. Immunol. 35: 1482-1490
91. Chang, C.J. et al. 2006. Placenta-derived multipo-tent cells exhibit immunosuppressive properties that are enhanced in the presence of interferon-gamma. Stem Cells 24: 2466-2477
92. Dong, H. et al. 2002. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8: 793-800
93. Fong, L. & E.J. Small. 2008. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J. Clin. Oncol. 26: 5275-5283
94. Hirano, F. et al. 2005. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 65: 1089-1096
95. Wong, R.M. et al. 2007. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int. Immunol. 19: 1223-1234
96. Hori, S., T. Nomura & S. Sakaguchi. 2003. Control of regulatory T cell development by the transcription factor Foxp3. Science 299: 1057-1061
97. Nishizuka, Y. & T. Sakakura. 1969. Thymus and reproduction: sex-linked dysgenesia of the gonad after neonatal thymectomy in mice. Science 166: 753-755
98. Sakaguchi, S. et al. 1995. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155: 1151-1164
99. Smith, T.R. & V. Kumar. 2008. Revival of CD8+ Treg-mediated suppression. Trends Immunol. 29: 337-342
100. Wang, L. et al. 2008. Programmed death 1 lig-and signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proc. Natl. Acad. Sci. USA 105: 9331-9336
101. Wing, K. et al. 2008. CTLA-4 control over Foxp3+ regulatory T cell function. Science 322: 271-275
102. Elpek, K.G. et al. 2007. Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling. J. Im-munol. 179: 7295-7304
103. Hombach, A.A. et al. 2007. Effective proliferation of human regulatory T cells requires a strong cos-timulatory CD28 signal that cannot be substituted by IL-2. J. Immunol. 179: 7924-7931
104. Aggarwal, S. & M.F. Pittenger. 2005. Human mes-enchymal stem cells modulate allogeneic immune cell responses. Blood 105: 1815-1822
105. Casiraghi, F. et al. 2008. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J. Immunol. 181: 3933-3946
106. Di Ianni, M. et al. 2008. Mesenchymal cells recruit and regulate T regulatory cells. Exp. Hematol. 36: 309-318
107. Djouad, F. et al. 2003. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 102: 3837-3844
108. Ahmadzadeh, M. et al. 2008. FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions. Blood 112: 4953-4960
109. Clark, R.A. et al. 2008. Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. J. Exp. Med. 205: 2221-2234
110. Curiel, T.J. et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10: 942-949
111. Liyanage, U.K. et al. 2002. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169: 2756-2761
112. Woo, E.Y. et al. 2002. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit au-tologous T cell proliferation. J. Immunol. 168: 4272-4276
113. Ahmadzadeh, M. & S.A. Rosenberg. 2006. IL-2 administration increases CD4 +CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 107: 2409-2414
114. Schuchter, L.M. 2004. Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose? J. Clin. Oncol. 22: 7-10
115. Atkins, M.B. et al. 1999. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17: 2105-2116
116. Flaherty, L.E. et al. 2001. Outpatient biochemother-apy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials. J. Clin. Oncol. 19: 3194-3202
117. Rosenberg, S.A. et al. 1985. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 313: 1485-1492
118. Smith, F.O. et al. 2008. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res. 14: 5610-5618
119. Tarhini, A.A. et al. 2007. Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J. Clin. Oncol. 25: 3802-3807
120. Abdel-Wahab, Z. et al. 1994. Transduction of human melanoma cells with interleukin-2 gene reduces tumorigenicity and enhances host antitumor immunity: a nude mouse model. Cell Immunol. 159: 26-39
121. Zatloukal, K. et al. 1995. Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. Assessment of critical cellular and molecular parameters. J. Immunol. 154: 3406-3419
122. Powell, D.J., Jr. et al. 2007. Inability to mediate prolonged reduction of regulatory T Cells after transfer of autologous CD25-depleted PBMC and interleukin-2 after lymphodepleting chemotherapy. J. Immunother. 30: 438-447
123. Jones, E. et al. 2002. Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun. 2: 1
124. Dannull, J. et al. 2005. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 115: 3623-3633
125. Attia, P. et al. 2005. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J. Im-munother. 28: 582-592
126. Kirkwood, J.M. et al. 2008. Next generation of immunotherapy for melanoma. J. Clin. Oncol. 26: 3445-3455
127. Maker, A.V., P. Attia & S.A. Rosenberg. 2005. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J. Immunol. 175: 7746-7754
128. Reuben, J.M. et al. 2006. Biologic and immunomod-ulatory events after CTLA-4 blockade with ti-cilimumab in patients with advanced malignant melanoma. Cancer 106: 2437-2444
129. Van Der Bruggen, P. et al. (1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643-1647
130. Rosenberg, S.A., J.C. Yang & N.P. Restifo. 2004. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10: 909-915
131. Arce, C. et al. 2006. A proof-of-principle study of epigenetic therapy added to neoadjuvant Doxoru-bicin cyclophosphamide for locally advanced breast cancer. PLoS ONE 1: e98
132. Chen, K.G. et al. 2005. Principal expression of two mRNA isoforms (ABCB 5alpha and ABCB 5beta) of the ATP-binding cassette transporter gene ABCB 5 in melanoma cells and melanocytes. Pigment Cell Res. 18: 102-112
133. Jin, L. et al. 2006. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med. 12: 1167-1174
134. Sigalotti, L. et al. 2008. Cancer testis antigens in human melanoma stem cells: expression, distribution, and methylation status. J. Cell Physiol. 215: 287-291
135. Dudley, M.E. et al. 2001. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J. Im-munother. 24: 363-373
136. Liu, K. & S.A. Rosenberg. 2001. Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of spe-cific antitumor activity. J. Immunol. 167: 6356-6365
137. Phan, G.Q. et al. 2003. Cancer regression and au-toimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 100: 8372-8377
138. Antony, P.A. et al. 2005. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174: 2591-2601
139. Frank, N.Y. et al. 2003. Regulation of progenitor cell fusion by ABCB5 P-glycoprotein, a novel human ATP-binding cassette transporter. J. Biol. Chem. 278: 47156-47165